Company intelligence / Profile preview

Vysis

Downers Grove, Illinois, USA

Ownership: Private
Development stage: Other

Overview

Vysis is a pioneer in the field of molecular diagnostics, best known for developing and commercializing Fluorescence In Situ Hybridization (FISH) technology. The company provides a wide range of genomic tests used to identify genetic abnormalities in oncology and prenatal health. Its most prominent products include the PathVysion HER-2 DNA Probe Kit, a critical companion diagnostic for breast cancer treatment, and the UroVysion kit for bladder cancer detection. Following its acquisition by Abbott Laboratories in 2001, Vysis became the foundation of Abbott Molecular. The brand continues to be a global leader in providing high-precision tools for personalized medicine.

Therapeutic areas: OncologyWomen's Health
Modalities: DiagnosticDevice
Industry: Molecular Diagnostics

Partnerships

GenentechPfizer

Beyond the preview

Go deeper on Vysis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vysis.

Explore the full profile